The apomorphine test in gait disorders associated with Parkinsonism

Clinical Neuropharmacology

Volumn 19, Issue 2, 1996, Pages 171-176

  Linazasoro, Gurutz ^a  

^a U de Parkinson y Trastornos del M   (Spain)

Author keywords

Apomorphine; Freezing; Neurochemical substrate

Indexed keywords

APOMORPHINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DROWSINESS; FEMALE; GAIT DISORDER; HUMAN; IMMOBILIZATION; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0029988567     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619020-00006     Document Type: Article

References (19)

1. Sudarski L. Gait disorders in the elderly. N Engl J Med 1990;322:1441-6.
2. Null SG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993;43:268-79.
3. Sudarski L. Director. Gait disorders in the elderly. AAN Meeting 1993 Syllabus 1993;123:1-66.
4. Atchinson PR, Thompson PD, Frackowiak RSJ, Marsden CD. The syndrome of gait ignition failure: a report of six cases. Mov Disord 1993;8:285-92.
5. Achiron A, Ziv I, Goren M, et al. Primary progressive freezing gait. Mov Disord 1993;8:293-97.
6. Giladi N, McMahon, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992;42:333-9.
7. Tohgi H, Abe T, Takahashi S. The effects of L-Threodops on the total norepinephrine and dopamine concentrations in the CSF and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993;5:27-34.
8. Narabayashi H, Kondo T, Results of a double blind study of L-Threodops in parkinsonism. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. New York: Macmillan. 1988;279-92.
9. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Park Ridge, NJ: Parthenon Publishing. 1992;89-113.
10. Hughes A, Lees AJ, Stern G. The apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990;2:32-4.
11. Oertel WH, Gasser T, Ippisch R, et al. Apomorphine test for dopaminergic responsiveness. Lancet 1989;1:1263.
12. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
13. Lang AET, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309.
14. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988;38:1553-7.
15. Quinn NP, Perlmutter JS, Marsden CD. Acute administration of DL-Threodops does not affect the freezing phenomenon in parkinsonian patients. Neurology 1984;34(suppl 1):149A.
16. Suzuki T, Sakoda S, Veji M, et al. Treatment of parkinsonism with L-Threodops. Neurology 1984;34:1446-50.
17. Reches A. Noradrenergic influences on dopaminergic function and the pharmacology of dops: implication for Parkinson's disease. Clin Neuropharmacol 1985;8:249-59.
18. Lees AJ. Dopamine agonists: a look at apomorphine. In: Agid Y, ed. Current trends in the treatment of Parkinson's disease. London: John Libbey, 1992;69-76.
19. Eidelberg E, Waldem SG, Nyngen LH. Locomotor control in macaque monkeys. Brain 1981;104:647-63.